Novacea Terminates Asentar Phase III For Prostate Cancer, But Sees Hope For Treatment In Pancreatic Cancer

Novacea and partner Schering-Plough aim to investigate higher death rate in Asentar arm, move forward in other oncology indications, Novacea CEO says.